Your best medicine news resource
Nov 21st 2008Drug InformationParkinson's Disease
A new study being published in this Friday’s online edition of Cell will help answer the question, what causes Parkinson’s disease? One of the most pressing questions in the medical research into Parkinson’s disease is what causes the sensitive cells in the brain to die in the first place.
More: continued here
Nov 21st 2008Drug InformationParkinson's Disease
Mayo Clinic (http://www.mayoclinic.org) researchers have developed a method to reduce the production of alpha-synuclein in the brain. Alpha-synuclein is a protein that is believed to be central to the cause of Parkinson’s disease (http://www.mayoclinic.org/parkinsons- disease).
More: continued here
Oct 29th 2008Drug InformationParkinson's Disease
Novartis Pharmaceuticals Corporation today announced the launch of two new FDA-approved dosage strengths of Stalevo(R) (carbidopa, levodopa and entacapone), which is indicated for certain people with Parkinson’s disease who experience end-of-dose “wearing off”. The approval of Stalevo 75 and 125 tablets (18.75 mg carbidopa, 75 mg levodopa, 200 mg entacapone and 31.
More: continued here
Your best medicine news resource
